Mostrar el registro sencillo del ítem
| dc.contributor.author | Castellani, Carlo | |
| dc.contributor.author | Mondéjar-López, Pedro | |
| dc.contributor.author | Van-Goor, Fredrick | |
| dc.contributor.author | Quon, Bradley-S | |
| dc.contributor.author | Alghisi, Federico | |
| dc.contributor.author | Fabrizzi, Benedetta | |
| dc.contributor.author | Ramsey, Bonnie | |
| dc.contributor.author | Taylor-Cousar, Jennifer-L | |
| dc.contributor.author | McKone, Edward-F | |
| dc.contributor.author | Tullis, Elizabeth | |
| dc.contributor.author | Weinstock, Tanya-G | |
| dc.contributor.author | Tan, Vincent | |
| dc.contributor.author | Ahluwalia, Neil | |
| dc.contributor.author | Mahic, Milada | |
| dc.contributor.author | Liu, Lingyun | |
| dc.contributor.author | Saayman, Sheena | |
| dc.contributor.author | Altshuler, David | |
| dc.contributor.author | Waltz, David | |
| dc.contributor.author | Mall, Marcus-A | |
| dc.contributor.author | Fajac, Isabelle | |
| dc.date.accessioned | 2026-09-17T12:11:25Z | |
| dc.date.available | 2026-09-17T12:11:25Z | |
| dc.date.issued | 2026-02-01 | |
| dc.identifier.issn | 1073-449X | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/28029 | |
| dc.description.abstract | RATIONALE: Elexacaftor/tezacaftor/ivacaftor, a CF transmembrane conductance regulator (CFTR) modulator, stabilizes and restores F508del-CFTR function, which is the most common CFTR variant. In multiple clinical and real-world studies, elexacaftor/tezacaftor/ivacaftor was shown to be safe and highly effective in people with CF carrying at least one F508del-CFTR (?80% of people with CF). OBJECTIVES: To characterize the response of rare, non-F508del CFTR variants to elexacaftor/tezacaftor/ivacaftor in vitro, and in clinical and real-world studies. METHODS: We engineered Fischer rat thyroid (FRT) cells each of which express 1 of 620 rare exonic CFTR variants present in public databases and evaluated their in vitro response to elexacaftor/tezacaftor/ivacaftor. We evaluated efficacy and safety of elexacaftor/tezacaftor/ivacaftor in a 24-week randomized, placebo-controlled, Phase 3 trial (445-124) in participants with 1 of 18 rare variants and no F508del and in a real-world study (CFD-016) in people carrying 82 rare variants and no F508del. MEASUREMENTS AND MAIN RESULTS: In FRT cells, 518 of 620 (84%) rare variants responded to elexacaftor/tezacaftor/ivacaftor. In 445-124, mean improvements were seen in the primary endpoint of percent predicted FEV1 (9.2 percentage points [95% CI: 7.2, 11.3; P < .0001]), and secondary endpoints of sweat chloride (-28.3 mmol/L [95% CI: -32.1, -24.5 mmol/L; P < .0001]) and CFQ-R RD (19.5 points [95% CI: 15.5, 23.5; P < .0001]). In CFD-016, improvements in lung function were seen after treatment initiation. CONCLUSIONS: In vitro, clinical, and real-world data support elexacaftor/tezacaftor/ivacaftor treatment in people carrying a range of CFTR variants and no F508del. The response of 84% of rare CFTR variants that produce protein to protein-stabilizing therapy suggests variants in many regions of the protein causes disease via protein destabilization. | |
| dc.language.iso | eng | |
| dc.publisher | OXFORD UNIV PRESS | |
| dc.rights | Atribución/Reconocimiento-NoComercial 4.0 Internacional | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/deed.es | * |
| dc.subject.mesh | Cystic Fibrosis/drug therapy/genetics | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Cystic Fibrosis Transmembrane Conductance Regulator/genetics/drug effects | |
| dc.subject.mesh | Indoles/therapeutic use | |
| dc.subject.mesh | Animals | |
| dc.subject.mesh | Quinolones/therapeutic use | |
| dc.subject.mesh | Double-Blind Method | |
| dc.subject.mesh | Aminophenols/therapeutic use | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Rats | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Benzodioxoles/therapeutic use | |
| dc.subject.mesh | Pyridines/therapeutic use | |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Pyrazoles/therapeutic use | |
| dc.subject.mesh | Drug Combinations | |
| dc.subject.mesh | Pyrrolidines/therapeutic use | |
| dc.subject.mesh | Rats, Inbred F344 | |
| dc.subject.mesh | Adolescent | |
| dc.subject.mesh | Quinuclidines/therapeutic use | |
| dc.subject.mesh | Young Adult | |
| dc.subject.mesh | Pyrroles/therapeutic use | |
| dc.subject.mesh | Quinolines | |
| dc.title | Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 41738096 | |
| dc.relation.publisherversion | https://academic.oup.com/ajrccm/article/212/2/327/8435645 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1093/ajrccm/aamaf001 | |
| dc.journal.title | AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | |
| dc.identifier.essn | 1535-4970 |